Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Just assumed Charles would never surrender his life’s work.
I must have missed something. Where do you see that the IP left BGEN?
April 26th PR...
Sagaliam Acquisition Corp. Announces Novation Agreement with Enzolytics, Inc.
Sagaliam Acquisition Corp.
Fri, Apr 26, 20246 min read
NEW YORK, NY / ACCESSWIRE / April 26, 2024 / Sagaliam Acquisition Corp. ("SAGAU", "SAGA", SAGAR") (the "Company") announced that Sagaliam entered into a Novation Agreement with Enzolytics, Inc. (OTC PINK:ENZC), Biogenysis, Inc. (BGEN), and Virogentics, Inc. (VIRO) (together the "Parties"). ?Under this restructured agreement SAGA retains 100% ownership of VIRO, ITV-1, the nutraceutical products and license along with VIRO's other assets. This agreement transferred ownership of Biogenysis, Inc. ("BGEN") and it's IP, patents and associated asset being developed back to ENZC in exchange for a reduction of the price from $450,000,000 to $290,000,000 with the dividend of the purchase shares to come directly to the ENZC shareholders from SAGA. The Parties believe this will significantly shorten the time needed to obtain regulatory approval to initiate the dividend of the 29 million SAGA shares issued for the purchase of VIRO. All other terms and conditions of the purchase agreement, including the make-whole provision relating to the 29 million SAGA shares, remain in place.
Barry Kostiner, the CEO of Sagaliam, commented, "After the Sagaliam - Enzolytics transaction was closed in September, we have worked together with the Enzolytics management team to tweak the details for mutual benefit. We are excited about moving forward with the Virogentics team. The ITV-1 therapy has potential to significantly improve effectiveness and reduce costs of the standard of care for HIV. Additionally, ITV-1 is believed to have therapeutic application to other chronic conditions including diabetes, cancer and other conditions known to be impacted by peptide therapies targeting inflammation. Our IPF nutraceutical has received strong consumer approval, and we will be ramping up our marketing efforts, in parallel with our other nutraceutical products. Through the Novation Agreement, return of Biogenysis to Enzolytics, and reduction of shares issued, we believe that we have a strong foundation for building a valuable pharmaceutical company with global impact, in partnership with our colleagues at Enzolytics. We are also working with Enzolytics on building the sales, marketing and distribution infrastructure for our nutraceutical products."
Steve Sharabura, the CEO of Enzolytics, commented, "The Novation Agreement is an exciting development for Enzolytics. It serves as a solid foundation for building both Enzolytics and Sagaliam as significant biotech companies that are independent entities, but that work closely together. Enzolytics is proud to be a major shareholder in Sagaliam. The two companies have several initiatives in the works, specifically in the areas of medical testing, medical devices and an expanded nutraceutical product line. Negotiations are ongoing between Sagaliam and Enzolytics on these matters."
Harry Zhabilov, the Chief Science Officer of Virogentics, commented, "With the completion of the Novation Agreement, we have visibility to funding and the success of both companies. We now have a platform that allows us to implement our vision of bringing our technology to commercial implementation. We are also in advanced discussions with multiple synergistic biotech companies that are interested in joining our platform. After much anticipation, we are excited about moving forward on bringing our therapies to improve the lives of many patients with multiple chronic conditions, as well as increasing the near-term revenue of our nutraceutical products."
About Sagaliam Acquisition Corp.
We are a blank check company incorporated under the laws of the State of Delaware on March 31, 2021 for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses or entities. Sagaliam intends to continue to pursue the consummation of a business combination with an appropriate target.
Virogentics, a subsidiary of Sagaliam, is advancing multiple therapeutics targeting numerous infectious diseases. One patented and clinically tested compound, ITV-1 (Immune Therapeutic Vaccine-1), is a suspension of Inactivated Pepsin Fraction (IPF), covered by U.S. Patent Nos. 8,066,982 and 7,479,538. Studies have shown it to be effective in treating HIV/AIDS. ITV-1 has also been shown to modulate the immune system.
DOGONE all tha IP left with Charles and Chandra and unless we have a miracle happen we may not have a ticket to ride. I didn’t invest in HARRY or anything he has. Clone 3 is what I put my money on and the AI was to be the bonus.
You're a class act docsetc.
Thanks for all of your efforts.
Well, since I'm the one that found the lab-lights had been turned off myself and posted the pictures here, and now tell you that its best to sit and wait on ENZC, I must have reasons for it, right basher?
Look, we all had good discussions about what was going wrong at ENZC, and I can tell you on good authority, we, for some good conjecture and fact-sharing, did have a lot of it right, as to what was happening, but it was a flipped-situation on how it was happening.
So now, on good information that became available, I will wait and see about ENZC. I was ready to sell off on a spike, but now I will wait until I see the right PR or public announcement that rings true before I act. I have good reason to hold and believe that the work on Clone3 and Clone7 will see the light of day sometime in the not-so-forboding future.
I will tell you, like I posted right after the last PR, I have no faith in the new 'Medical Device Sales and Distribution' angle, but I have faith in some other factors I believe will arise.
GLTY And don't ever challenge my integrity again.
continued.....
Enzolytics, Inc. Overview
Enzolytics, Inc. is a drug development company committed to commercializing its proprietary monoclonal antibodies and proteins to treat debilitating infectious diseases.
Biogenysis, a subsidiary of Enzolytics, uses proprietary techniques to produce fully human monoclonal antibodies (mAbs) against infectious diseases. The technology is currently being employed to produce monoclonal antibody therapeutics for treating the CoronaVirus (SARS-CoV-2), HIV-1 and the Feline Leukemia Virus. The Company has also identified conserved epitopes on and has plans to produce mAbs targeting many other viruses, including H1N1 Influenza, HTLV1 & HTLV2, Leukemia Virus, Herpes Simplex I Virus, Respiratory Syncytial Virus (RSV), Smallpox Virus, Rabies, Influenza A, Influenza B, Ebola Virus, Epstein Barr Virus, and Monkey Pox Virus. The Company has also analyzed epitopes of animal viruses and plans to produce mAbs for treating these animal viruses.
Virogentics, a subsidiary of Enzolytics, is advancing multiple therapeutics targeting numerous infectious diseases. One patented and clinically tested compound, ITV-1 (Immune Therapeutic Vaccine-1), is a suspension of Inactivated Pepsin Fraction (IPF), covered by U.S. Patent Nos. 8,066,982 and 7,479,538. Studies have shown it to be effective in treating HIV/AIDS. ITV-1 has also been shown to modulate the immune system.
This Aug 24th 2023 PR gives us a breakdown of VIRO and BEGN and what they contain.
ACCESSWIRE
Biogenysis’ International Patent Application, Covering Its Anti-SARS-CoV-2 Monoclonal Antibodies, Advances to Prosecution in Europe and as a U.S. National Stage Application.
ACCESSWIRE· Enzolytics, Inc.
Enzolytics, Inc.
Thu, Aug 24, 202310 min read
COLLEGE STATION, TX / ACCESSWIRE / August 24, 2023 / Biogenysis, Inc. (OTC PINK:ENZC) (or the "Company"). Biogenysis, a subsidiary of Enzolytics, Inc., announces the progress of its Patent Cooperation Treaty (PCT) application covering its inventions relating to Anti-SARS-CoV-2 Monoclonal Antibodies. The PCT application has now advanced to filing as a U.S. National Stage Application in the U.S. Patent Office and as a formal European Patent Organization (EPO) application. The EPO application makes possible coverage in the 39 contracting countries within the EPO. These countries include all of the countries in the European Union, the United Kingdom and the extensive list totally 39 member countries throughout Europe and adjacent regions. https://www.epo.org/about-us/foundation/member-states.html.
The pending applications contain 23 separate patent claims covering (1) the 19 discovered highly conserved antigens and epitopes (sites) on the SARS CoV-2 virus, (2) antibodies that bind to the disclosed antigens and epitopes, (3) vaccines based on the antigens, (4) methods of treating, preventing, or reducing the risks of SARS CoV-2 infection with the antigens or binding proteins, and (5) methods and kits for detecting or diagnosing infection by SARS CoV-2 using the antigens or binding proteins.
Through computer analysis (Artificial Intelligence (AI)), the Company discovered 19 immutable conserved virus sites on the COVID-19 virus by analyzing 2.8 million SARS CoV-2 isolates. This analysis identified these critical, conserved, immutable epitopes of the virus. These sites are now claimed as patentable based on their novel specificity and the finding that they are conserved on SARS-CoV-2. This is significant because antibodies produced to bind to these conserved, immutable sites can neutralize the virus without the possibility of "virus escape" due to virus mutation. Specifically, virus mutants will still contain these target sites allowing these specialized monoclonal antibodies to neutralize the virus even as it mutates.
The Company's patent applications claim the use of any one identified epitope or any combination of any of the multiple identified epitopes in any of the following ways:
For producing a therapeutic monoclonal antibody to treat the CoronaVirus.
For making a vaccine against the CoronaVirus.
For creating related prophylactic/therapeutic methods relating to the epitopes/antigens.
For use in any diagnostic test to identify whether a person has the CoronaVirus.
The Company has produced and is producing fully human monoclonal antibodies against these claimed sites. The International Patent Office has confirmed these discoveries as being novel and inventive, capable of being patented and claimed exclusively for a 20-year term in each member country under the Patent Cooperation Treat in which the Company pursues these claims.
The Company also has similar PCT applications pending covering discovered immutable conserved epitopes (binding sites) on the HIV virus and the animal Feline (cat) Leukemia Virus (FeLV). The Company has also analyzed the amino acid sequences on numerous other human and animal viruses and plans to also produce anti-mAbs targeting these sites and will file for U.S. and international patents on these discoveries. These discoveries include the Company's findings from analyzing the human viruses H1N1 Influenza, HTLV1 & HTLV2, Leukemia Virus, Herpes Simplex I Virus, Respiratory Syncytial Virus (RSV), Smallpox Virus, Rabies, Influenza A, Influenza B, Ebola Virus, Epstein Barr Virus, and Monkey Pox Virus.
The Company has also analyzed and identified conserved and immutable epitopes in animal viruses including Equine Infectious Anemia Virus, Feline Immunodeficiency Virus, Koala Retrovirus Virus, and Elephant Endotheliotropic Herpes Virus. Using the Company's technology currently being used to produce monoclonal antibodies against human viruses, therapeutic mAbs may be produced to treat these animal viruses.
The Company fully expects the issuance of multiple international patents covering these discoveries accomplished through the Company's unique process using computer analysis (AI) to identify conserved, immutable epitopes on the target virus. Biogenysis' proprietary AI platform, invented by Dr. Gaurav Chandra, Biogenysis' CEO, has been used to analyze the sequences (structure) of 2.8 Million SARS-CoV-2 virus isolates to identify conserved sites. As a part of this process, 3-dimensional models of these conserved targets were generated, and the targets were analyzed for linearity, accessibility by antibodies, and neutralizability by antibodies. From this, Biogenysis scientists are producing multiple broadly neutralizing antibodies targeting these multiple conserved, immutable epitopes on the targeted virus. The monoclonal antibodies directed against these targets will expectedly be universal, durable, broadly neutralizing, and unaffected by virus mutation.
The Company considers the expected patent protection to be highly significant, recognizing that for a monoclonal antibody to be effective (that is, to be fully capable of neutralizing a virus), it must target an immutable site on the virus. Otherwise, virus mutation will render the therapeutic ineffective. Biogenysis' methodology for producing monoclonal antibodies is unique and innovative, unlike those other biotech companies employ. The Company's antibodies are made from human "immune-B cells" obtained from convalescent individuals (or animals in the case of veterinarian monoclonal antibodies) who have recovered from the target virus. The Company's monoclonal antibodies are not "humanized" but are fully human monoclonal antibodies where the original antibody affinity and specificity are maintained, and the chances of immunogenicity are minimized.
The Company believes its discoveries will be significant to the success of the Company. Although the COVID-19 pandemic was reported to be over, it is now recognized that COVID-19 will be with us from year to year. The global market size for effective treatments in 2022 was $16.43 billion. The global Monoclonal Antibodies market size was $185.50 Billion in 2021, with an expected compound annual growth rate (CAGR) of 11.30% from 2022 to 2030.
The Company's near-term objective is to collaborate with pharma entities and license its technology or partner with major pharma entities now producing therapies for COVID-19.
Regarding the Company's therapeutic against HIV, the Company has produced a fully human anti-HIV monoclonal Antibody, Clone 3. The Company is now producing additional anti-HIV mAbs to be used in combination. Experts agree that a cure for HIV may be found in the production and administration of multiple anti-HIV monoclonal antibodies. This is the Company's goal. The Company has successfully produced and tested, in vitro, one HIV monoclonal antibody (Clone 3) and has identified 7 additional immutable conserved sites on the HIV virus against which it is in the process of producing anti-monoclonal antibodies. These antibodies will be produced as fully human, with the starting point being human "immune-B cells" from long-term non-progressor HIV patients. This production is being conducted with pharmaceutical entities to accelerate the process of production and testing of the monoclonal antibodies.
In 2021, the global HIV drugs market was $30.46 billion, with this market projected to grow to $45.58 billion by 2028. The global Monoclonal Antibody market size was $185.50 Billion in 2021, with an expected compound annual growth rate (CAGR) of 11.30% from 2022 to 2030.
The global market for Human Monoclonal Antibodies in 2022 was $55 Billion.
The Company's near-term objective is collaboration with pharma companies producing treatments for HIV. The current HIV treatments available do not cure and must be taken for a lifetime. The Company is focused on licensing or partnering with major pharma entities now producing treatments for HIV. To accelerate and fully execute the successful production of the multiple monoclonal antibodies, the subject of the Company's intellectual property, the Company continuously engages with multiple pharma entities to accomplish the successful goal of production, testing, and delivery of successful therapeutics.
Gaurav Chandra, Biogenysis' CEO, stated, "Amid alarming concerns regarding COVID mutations, it is crucial to prioritize efforts towards achieving broader immunity against variants, longer-lasting protection, and preventing infection and transmission. Utilizing intranasal IgA monoclonal antibodies effectively attains high secretory IgA levels, reflecting mucosal immunity. The Biogenysis anti-COVID monoclonal antibodies, both IgG and IgA, being universal, broadly neutralizing, durable, and unaffected by mutations, are a critical solution to this pressing issue."
Charles Cotropia, Enzolytics' CEO, said, "We have a well-defined strategy for developing an Intellectual Property portfolio to secure significant patent protection covering our therapeutic discoveries in numerous countries around the world. With these rights secured, we will focus on potential partnering or licensing the technology to international pharmaceutical companies working in the areas in which we are focused. Obtaining international patent coverage will be significant in achieving this objective.
"The necessary technology is now in hand for producing these therapeutics for use in the treatment of many infectious diseases. The earlier announced plans for the sale of Biogenysis and Virogentics, subsidiaries of Enzolytics, to Sagaliam Acquisition Corp. (NASDAQ: SAGA), a special purpose acquisition company ("SPAC"), comes at an opportune time. Once completed, this transaction will provide Biogenysis and Virogentics with the capital that will make possible final development of the therapeutics now being produced."
lol, I think he's sleeping with BM, she has a hot passion for emailing hirer ups.
Bigtalan wants to send emails lol, imagine thinking you should have to send an email to get a remotely honest response, or any information at all, about the company you've invested in lol. I guess they're too stupid to communicate in any proper way, but an email should solve that!
No there aren't.
And please stop mentioning that you're from the great state of Texas.
Its an embarrassment.
I know we probably wont get a reply , but has anyone sent emails to Harry and Barry , asking simple questions that as a long time shareholders are due answers and not the same BS pr's we have been getting? Question on when the dividend date was or will be , will SAGA be tradeable and on what trading platform and when along with a few more. Still waiting on mine GLTA
So we're going from saving humanity, medical break-through antibodies to hawking vitamin C enhanced health food store supplements! C'mon! And if you haven't al ready, check out Chandra's latest happy tweets. What have they been doing for four years? For the love of God, When are we going to get some real information? There....I had to say it. LOL
Third Coast Fulfillment - http://www.thirdcoastfulfillment.com/
The address from the website is:
3810 Dacoma St
Houston, TX 77092
When I looked that up I found:
Wahlberg-McCreary Parts Plus
Auto parts & supply store
Permanently closed
3810 Dacoma St, Houston, TX 77092
Then I checked Third Coast Fulfillment with the Texas SOS
Mailing Address 3701 AVENUE F BAY CITY, TX 77414-7605
3701 Avenue F
Bay City, TX 77414
40,040 SF
Vacant Industrial Building
For Sale.
Before blindly believing a press release that Quotes Kostiner - verify everything then run.
IG
If this was what docset was having us wait for, it’s disappointing. Let’s hope something more is mentioned soooonn
red flag these owners are complete liars and theifs.the stock price is a nightmare less than a penny down from 90 cents.
The press release is more pumping garbage - the ENZC investors will believe anything these clowns tell them to believe.
"As part of the relationship with ETC Marketing, Sagaliam is expanding its product categories from nutraceuticals, to also include partnerships in the distribution of consumer medical devices and home tests for multiple indications."
Sagaliam was an empty shell they didn't have a product line - they were a blank check company or SPAC.
Hopefully, no one will believe or fall for this pumping again.
IG
We?? Advising people to wait this out while they lose thousands of dollars is… nevermind believe and do as you please good luck!!!!
Holy mother of Jesus - SAGA isn't a SPAC - they were delisted.
"This is a strange PR because, at least to my knowledge, it has not been confirmed yet as to whether this SAGA/Enzolytics SPAC Deal is still on or is defunct."
First there never was a deal with SAGA - they were delisted from Nasdaq and they still aren't listed on the OTC.
When Nasdaq delisted Sagaliam there was no longer a deal.
IG
Thank you. I would tend to agree. I doubt the owners of these highly prized patents would just sell them off, leaving themselves no assets. Only a lunatic would do that or believe that. And the owners of Enzolytics are NOT lunatics. We need to wait & see how the dust settles. Once we have full knowledge of the facts (which we do not have now), we can judge and make assessments.
Only a fool makes ass-umptions lacking full knowledge. There are just too many unanswered questions yet about ENZC & SAGA & SPAC Deal for anyone to speculate at this time.
ALL of the enzc scumbags are to blame for this loss of Stock price .I hope and pray they rot in hell.
There isn't any prize patents - they have been pumping those patents for years.
What don't you understand that ENZC doesn't own any patents. The Zhabilov Trust owns the 2 patents that are worthless.
IG
Regardless of the recent PR, with NO mention of Clone 3/7, I do NOT believe there's a ghost's chance in heaven that the Cotropias would sell their rights to their prize patents to SAGA, leaving NO Assets in Enzolytics. Only a lunatic would do that & CC & Joseph are NO lunatics!!! They've dedicated their whole lives to curing HIV-AIDS with their highly-coveted patents. And are continuing to file more Patent Apps for them all along, and succeeding in getting them approved, though takes time.
How about this one? zhabilov@att.net
https://www.otcmarkets.com/stock/ENZC/profile
On May 1, 2024, I tried to send an email to the address info@enzolytics.com. I received an error message saying that the email address info@enzolytics.com does not exist.
Should be at .0003 at best, still another 90% crash to go
Because there are those that believe in get rich schemes, and that if you buy sub penny that you can become rich quickly.
It just depends how many fools jump into the scheme to make money for the ones that buy at the bottom.
This company, if we can even say that with a straight face, should be valued at zero.
Silly advice from someone that only wishes to pump this POS turd so that others will make the same mistake and give them a chance to exit.
From curing the world to becoming a marketing venture, I'd say the lights to this have been turned off.
And for the ones that claim that so and so ran off with the jewels, there were no jewels in the first place.
Why isn’t this at trips or zero yet?
This is a strange PR because, at least to my knowledge, it has not been confirmed yet as to whether this SAGA/Enzolytics SPAC Deal is still on or is defunct.
$ENZC on that PR
--
Third Coast Fullfillment in Houston does exist, so that is a plus . Not a fantastic website,but a building is there on the address check
http://www.thirdcoastfulfillment.com/about-us.html
--
Strange how Sagalium is involved (TBD) in this
see the article out today on ENZC PR.
https://www.otcmarkets.com/stock/ENZC/news/Enzolytics-Inc-Announces-Formation-of-Marketing-Company-in-Partnership-with-Third-Coast-Fulfillment?id=439160
--
For sure BGEN and VIRO , not included in any format in that PR, which is not surprising.
--
The "Curious Case of ENZC" continues
This new PR is hilarious, just like a typical otc scam pivot when original narrative is dead, pathetic, fake, more lies
****HPOTD****
"Harry's Pump Of The Day"
https://finance.yahoo.com/news/enzolytics-inc-announces-formation-marketing-134000521.html?.tsrc=rss
Social media trading got to love it, The trading club is back. Trade the false swings they love to create. Go ENZC….
Wait for the official explanation from Charles and don’t react to ground noise.
Still got a few whales swimming.
Long term chart pattern tell you all you need to know about this.
The new Enzolytics X account tells you all you need to know about this stock
I cannot tell you how much I appreciate you. THANK YOU!!!
Btw, aren't you in Texas? It seems you are, based on what you said about your trip to College Station to see ENZC lab at TAMU.
I am in Houston, btw~ I have an Email address, bonniemacsattic@gmail.com, in case you want to reach me there.
Again, Thx SO much!
Thank you so much, MAGA, for replying! I ditto everything you just said, 100%. I am still in shock. Just totally baffled. Someday, hopefully soon, all will come to light. And maybe even be resurrected like a phoenx, but that may be holding out for too much. We shall see! But it's been a huge disappointment with a tragic ending at this point.
I really wonder what's goin on in CC's head these days. I truly believe he was sincere in his efforts to make this thing fly, but perhaps he just gave up & settled with the only best funding he could find, i.e., with SAGA. Perhaps they fed him a line or two, and he was hoping on hope they'd get their past financial mistakes corrected. Just like he thought he might be able to clear up Harry's mess, but also saw he had connections in Europe for lab/trials, etc, & deep-pockets for funding (which may have also fizzled out, too-- who knows?!).
BUT IF ANYthing ever decent comes out of all this, I'll be pleasantly surprised & cheering them on in the front lines! Stranger things may've happened!
Maybe we've learned from our mistakes, and Down the Road, Better Deal!
I wish you all the best!
RDGL website up today: radiogelusa. com RDGL UP 20% today.
UP 68% in last 5 days.
Thanks docset for helping us figure out wtfk is going on at ENZC.
Have a good day
I can assure you that Charles and Chandra own the IP's at present, and they are not fully removed from ENZC at this time. BGEN is mostly a non-entity at present, being held in readiness for a new interation.
There is a lot going on, and its best to sit tight on your ENZC investments, while some things play through. ENZC is transitioning, but not the way you think.
GLTY
And there are far bigger reasons they held every share they ever owned at ENZC, which is the case!
Followers
|
1245
|
Posters
|
|
Posts (Today)
|
5
|
Posts (Total)
|
200034
|
Created
|
01/07/10
|
Type
|
Free
|
Moderators Homebrew Timing101 archilles SeniorApollo |
Independent Valuation Report Pre Clinical Studies
Investments
___________________________________________________________________________________
Press Release July 20-2021
Enzolytics Announces the Signing of a Letter of Intent with Creative Biolabs, Inc.
for Licensing and Commercialization of anti-HTLV-1 Monoclonal Antibodies
https://www.creative-biolabs.com/
https://finance.yahoo.com/news/enzolytics-announces-signing-letter-intent-113000339.htm
________________________________________
Press release July 21-2021
Enzolytics and Lonza Bioscience Combine Technologies to Fast-track Development and
Production of Anti-HIV and Anti-SARS-CoV-2 Monoclonal Antibodies produced by Enzolytics
https://www.lonza.com/
https://www.bloomberg.com/press-releases/2021-07-21/enzolytics-and-lonza-bioscience-combine-technologies-to-fast-track-development-and-production-of-anti-hiv-and-anti-sar
_________________________________________
July 22 INTERVIEW
with
James Hicks, Charles Cotropia and Gurav Chandra
http://www.youtube.com/watch?v=mdljO9VLgj0
______________________________________________________________
COLLEGE STATION, TX August 25, 2021
Important Excerpt from this news progress update.
>>>>>><<<<<<
"The monoclonal antibodies being produced by Enzolytics against the CoronaVirus target 19 conserved immutable sites on the virus, sites which the Company has now confirmed are conserved sites not only on the initial virus strains but also existing in the Delta and Lambda variants, as well as in the Alpha, Beta and Gamma variants."
Enzolytics Inc. and Samsung Biologics Announce
Development and Manufacturing Agreement for Anti-
HIV and Anti-SARS-CoV-2
Important Excerpt from this news progress update.
>>>>>><<<<<<
"Samsung Biologics (KRX: 207940. K.S.), a leading contract development and manufacturing organization and Enzolytics (ENZC), a drug development company committed to commercializing multiple proprietary therapeutics to treat debilitating infectious diseases, announced the signing of a strategic CDMO partnership agreement."_______
2000 North Central Expressway
Plano, TX 75074
972-292-9414
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |